REGENXBIO (NASDAQ:RGNX) Given “Buy” Rating at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. A number of other brokerages also recently issued reports on RGNX. Wall Street Zen raised REGENXBIO from a […]
Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. A number of other brokerages also recently issued reports on RGNX. Wall Street Zen raised REGENXBIO from a […]
